




RealRate

PHARMACEUTICAL 2019

Oncternal Therapeutics Inc.
Rank 322 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Oncternal Therapeutics Inc. Rank 322 of 371

The relative strengths and weaknesses of Oncternal Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Oncternal Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 415% points.

The company's Economic Capital Ratio, given in the ranking table, is -697%, being 365% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	31,208
Cost of Goods Sold	0
Intangible Assets	94
Liabilities, Current	5,210
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	641
Property and Equipment	19
Research and Development	29,669
Revenues	0
Selling, General and Administrative Expense	9,390

Output Variable	Value in 1000 USD
Assets	31,321
Liabilities	5,210
Expenses	39,059
Stockholders Equity	26,111
Net Income	-38,418
Comprehensive Net Income	-38,418
Economic Capital Ratio	-697%

